GLP-1 Resource Center

Why am I losing weight so fast on Ozempic, is that normal?

Rapid weight loss on GLP-1 medications is expected and is a sign the medication is working as intended. The speed of loss does have consequences worth understanding, because what you eat and how you move during rapid loss shapes your body composition on the other side of it.

What the clinical data shows

In STEP 1 (Wilding et al., NEJM 2021), semaglutide at 2.4mg weekly produced average weight loss of 14.9 percent of body weight over 68 weeks. In SURMOUNT-1 (Jastreboff et al., NEJM 2022), tirzepatide at 15mg weekly produced an average of 22.5 percent. These are averages. Individual patients often lose faster, particularly in the first three to six months when appetite suppression is most pronounced. A 2025 joint advisory from four professional societies (Mozaffarian et al., Obesity) reported caloric intake reductions of 16 to 39 percent across the GLP-1 drug class, which is the reason nutritional intake becomes harder to meet during this period.

Why the speed of loss shapes the quality of the outcome

A 2026 systematic review of 20 trials covering 15,782 people found that 25 to 39 percent of the weight lost on GLP-1 medications is fat-free mass, the share depending on the medication: 35.2 percent on semaglutide and 25.4 percent on tirzepatide.* That is the largest and most recent pooled analysis available, and it is the figure we use throughout the site. It is consistent with the SURMOUNT-1 DXA substudy (Look et al., Diabetes, Obesity and Metabolism, 2025, 255 enrolled and 160 analysed), which reported 74 percent of the body weight reduction as fat mass and 26 percent as lean mass.

Two things make that read less alarming than it first appears. In SURMOUNT-1 the placebo group lost a comparable share to tirzepatide, so this is weight loss behaving as weight loss rather than the medication doing something unusual. And fat-free mass measured by DXA includes water, glycogen and connective tissue, so it is not skeletal muscle alone. In practice this means two people can lose the same 20kg and arrive at different amounts of lean tissue, depending largely on protein intake and whether they moved against resistance while losing.

Most guidelines suggest 1.0 to 1.2 g/kg of body weight per day during active weight loss, and a 2026 review recommends 1.2 to 1.5 g/kg. A meta-analysis across 24 trials found that higher protein intake during energy restriction preserved 0.43kg more fat-free mass than standard protein intake, an effect the authors describe as modest. For creatine, a June 2026 JISSN meta-analysis of seven randomised trials in 608 postmenopausal women found gains in lean mass of 0.37kg and leg press strength of 7.5kg, but only at 5g or more daily combined with resistance movement, and no effect at 3g or less or without it. None of this is a promise about how you will look. It is a description of what the evidence has measured.

The TAKE approach

If your intake has fallen sharply, ask your clinician about bloodwork rather than working from symptoms. Where nutritional gaps are real, The Foundation System is formulated to support nutritional status, digestive comfort and electrolyte intake during treatment.* The Strength System is formulated to support lean mass alongside adequate protein and resistance movement.* Neither replaces food, and neither changes the rate at which you lose weight.

These statements have not been evaluated by the Food and Drug Administration. TAKE products are not intended to diagnose, treat, cure, or prevent any disease. Individual results vary. Always speak with your healthcare provider about medication side effects or medical concerns.
Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. References to these names on this page are for informational and descriptive purposes only and do not imply affiliation, sponsorship, or endorsement by, or partnership with, Novo Nordisk A/S, Eli Lilly and Company, or any other GLP-1 medication manufacturer.